Dajak Slavica, Culić Srđana, Stefanović Vedran, Lukačević Jelena
Department of Transfusion Medicine, Split University Hospital Centre, Split, Croatia.
Department of Paediatrics, Split University Hospital Centre, Split, Croatia.
Blood Transfus. 2013 Oct;11(4):528-32. doi: 10.2450/2013.0193-12. Epub 2013 Mar 5.
The aim of this study was to determine the relationship between non-RhD immunisation and the consequent development of haemolytic disease of the newborn in pregnant women with a history of red blood cell transfusion compared to those without a history of transfusion.
This retrospective cohort study included all pregnancies with red blood cell antibodies that were tested between 1993 and 2010. Data were obtained from the forms for immunisation tracking at the Department of Transfusion Medicine. Each form contained data on previous maternal transfusions, antibody specificities and whether the antibodies caused haemolytic disease of the newborn.
Clinically significant non-RhD antibodies was found in 214 of 108,000 pregnancies, of which the most frequent were anti-E (n =55), anti-K (n =54), and anti-c (n =52) antibodies. A history of red blood cell transfusion was identified in 102 (48%) of the pregnancies in which non-RhD antibodies were found (in 78% of the anti-K cases, 40% of the anti-c and 18% of the anti-E cases). Non-RhD antibodies caused haemolytic disease of the newborn in 44 cases of which 14 were very severe (2 anti-K, 8 anti-c, 3 anti-Rh17, 1 anti-E). The mother had a positive history of red blood cell transfusion in 39% of the cases of haemolytic disease of the newborn. Anti-c antibodies were involved in all cases with severe haemolytic disease of the newborn and a history of maternal red blood cell transfusion.
Primary prevention by using K-negative, Rhc-, RhE-, and RhC-compatible red blood cell transfusion for women younger than 45 years may prevent up to 40% of cases of haemolytic disease of the newborn. Rhc compatibile transfusion is the most important prevention strategy against severe haemolytic disease of the newborn caused by non-RhD antibodies.
本研究的目的是确定有红细胞输血史的孕妇与无输血史的孕妇相比,非RhD免疫与新生儿溶血病后续发展之间的关系。
这项回顾性队列研究纳入了1993年至2010年间检测出红细胞抗体的所有妊娠病例。数据来自输血医学部的免疫追踪表格。每份表格包含既往孕产妇输血情况、抗体特异性以及抗体是否导致新生儿溶血病的数据。
在108,000例妊娠中有214例发现具有临床意义的非RhD抗体,其中最常见的是抗-E(n = 55)、抗-K(n = 54)和抗-c(n = 52)抗体。在发现非RhD抗体的102例(48%)妊娠中发现有红细胞输血史(抗-K病例的78%、抗-c病例的40%和抗-E病例的18%)。非RhD抗体导致44例新生儿溶血病,其中14例非常严重(2例抗-K、8例抗-c、3例抗-Rh17、1例抗-E)。在39%的新生儿溶血病病例中母亲有红细胞输血阳性史。抗-c抗体与所有有严重新生儿溶血病且母亲有红细胞输血史的病例有关。
对于45岁以下女性,使用K阴性、Rhc-、RhE-和RhC相容的红细胞输血进行一级预防,可预防高达40%的新生儿溶血病病例。Rhc相容输血是预防由非RhD抗体引起的严重新生儿溶血病的最重要预防策略。